RESULTS FROM RECENT THERAPEUTIC TRIALS FOR OPPORTUNISTIC INFECTIONS (Ols) FROM THE UNITED STATES

AIDS ◽  
1994 ◽  
Vol 8 (Supplement 4) ◽  
pp. S15 ◽  
Author(s):  
W. D. Hardy ◽  
S. Bozzette ◽  
S. Safrin ◽  
J. Black ◽  
C. Farthing ◽  
...  
Keyword(s):  
United States ◽  
Opportunistic Infections ◽  
The United States ◽  
Therapeutic Trials

Intergroup Rhabdomyosarcoma Study: Update for Pathologists

1998 ◽  
Vol 1 (6) ◽  
pp. 550-561 ◽  
Author(s):  
Stephen J. Qualman ◽  
Cheryl M. Coffin ◽  
William A. Newton ◽  
Hiroshi Hojo ◽  
Timothy J. Triche ◽  
...  
Keyword(s):  
United States ◽  
Spindle Cell ◽  
The United States ◽  
Study Group ◽  
Fusion Genes ◽  
Therapeutic Trials ◽  
Fifth Generation ◽  
Molecular Studies ◽  
Histopathologic Features

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood, and 75% of such cases in the United States are reviewed at the Pathology Center for the Intergroup Rhabdomyosarcoma Study Group (IRSG). The first four generations of IRSG therapeutic trials (IRS I–IV) and supportive pathologic studies have generated a new International Classification of Rhabdomyosarcoma (ICR) that offers new morphologic concepts to the practicing pathologist. The objective of this report is to clearly define emerging histopathologic categories of RMS as defined by the ICR, and to emphasize correlative immunohistochemical or molecular studies. Emerging ICR variants of RMS place the patient in widely divergent prognostic categories (superior, botryoid or spindle cell variants; poor, solid alveolar or diffusely anaplastic variants). The cardinal histopathologic features of the ICR combined with results of studies of fusion genes seen with t(1;13) and t(2;13) will help delineate therapeutic subgroups of RMS for the fifth generation (IRS V) of IRSG studies. Consequently, it is imperative for the practicing pathologist to be familiar with the practical workup and diagnosis of RMS in childhood.

scholarly journals Cladosporium Species Recovered from Clinical Samples in the United States

2015 ◽  
Vol 53 (9) ◽  
pp. 2990-3000 ◽  
Author(s):  
Marcelo Sandoval-Denis ◽  
Deanna A. Sutton ◽  
Adela Martin-Vicente ◽  
José F. Cano-Lira ◽  
Nathan Wiederhold ◽  
...  
Keyword(s):  
United States ◽  
Opportunistic Infections ◽  
Large Subunit ◽  
The United States ◽  
Antifungal Drugs ◽  
Nuclear Ribosomal Dna ◽  
Clinical Samples ◽  
Large Set ◽  
Anatomic Site ◽  
Content Type

Cladosporiumspecies are ubiquitous, saprobic, dematiaceous fungi, only infrequently associated with human and animal opportunistic infections. We have studied a large set ofCladosporiumisolates recovered from clinical samples in the United States to ascertain the predominant species there in light of recent taxonomic changes in this genus and to determine whether some could possibly be rare potential pathogens. A total of 92 isolates were identified using phenotypic and molecular methods, which included sequence analysis of the internal transcribed spacer (ITS) region and a fragment of the large subunit (LSU) of the nuclear ribosomal DNA (rDNA), as well as fragments of the translation elongation factor 1 alpha (EF-1α) and actin (Act) genes. The most frequent species wasCladosporium halotolerans(14.8%), followed byC. tenuissimum(10.2%),C. subuliforme(5.7%), andC. pseudocladosporioides(4.5%). However, 39.8% of the isolates did not correspond to any known species and were deemed to comprise at least 17 new lineages forCladosporium. The most frequent anatomic site of isolation was the respiratory tract (54.5%), followed by superficial (28.4%) and deep tissues and fluids (14.7%). Species of the two recently described cladosporiumlike generaToxicocladosporiumandPenidiellaare reported for the first time from clinical samples.In vitrosusceptibility testing of 92 isolates against nine antifungal drugs showed a variety of results but high activity overall for the azoles, echinocandins, and terbinafine.

scholarly journals Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000–2010

2016 ◽  
Vol 214 (6) ◽  
pp. 862-872 ◽  
Author(s):  
Kate Buchacz ◽  
Bryan Lau ◽  
Yuezhou Jing ◽  
Ronald Bosch ◽  
Alison G. Abraham ◽  
...  
Keyword(s):  
United States ◽  
Opportunistic Infections ◽  
The United States

scholarly journals Timeline of COVID-19 and its therapeutics in the United States

2020 ◽  
Vol 3 (3) ◽  
pp. 01-04
Author(s):  
Pankaj Bansal
Keyword(s):  
United States ◽  
Severe Acute Respiratory Syndrome ◽  
Vaccine Development ◽  
The United States ◽  
Global Scale ◽  
The Novel ◽  
Therapeutic Trials ◽  
Rapid Spread ◽  
Novel Coronavirus ◽  
Poor Efficacy

The novel coronavirus was first discovered and reported in December 2019. Later termed the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COv-2) virus, rapid spread was detected in China. Overtime, SARS-COv-2 spread to various other countries requiring swift intervention on a global scale. As infection spread, several therapeutics have been investigated for Coronavirus Disease- 2019 (COVID-19), including remdesivir, lopinavir/ritonavir, hydroxychloroquine, dexamethasone, etc. Furthermore, rapid investigation and construction of several potential vaccines have begun, some of which are in late stage testing. We present a concise timeline representing the evolution of COVID-19, therapeutic trials, and vaccine development. Ultimately, evident by the overall poor efficacy of several medications investigated so far, vaccination success remains the most likely effective step to combat COVID-19.

Sign in / Sign up

Export Citation Format

Share Document